• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

EuropaBio Calls for More Transparency of Biosimilar Labels


EuropaBio has developed recommendations for changes to the Summary of Product Characteristics (SmPC) of biosimilars that would result in an enhanced level of transparency in the label.

EuropaBio members believe that the current EU approach to labeling does not reflect the specificities of biosimilars and that the SmPC of a biosimilar product should contain additional information to facilitate greater transparency for physicians and patients.

Based on interactions that EuropaBio had with various stakeholders including physicians and patients over recent years, we have concluded that label transparency would be enhanced by implementing the following small yet meaningful changes to the biosimilar SmPC:

  • Adding a statement with the definition of biosimilarity

  • Adding a direct link to the EPAR next to the biosimilarity statement

  • Moving the biosimilarity statement to the top of the SmPC

“The EMA and the European Commission are going to great lengths to increase  physicians’ and patients’ understanding of biosimilars”, said Ronald Jager, EuropaBio Healthcare Biotech Director, “We are convinced that a more transparent labeling approach would contribute to further facilitate the understanding and acceptance of biosimilars.”

Related Videos
Ashley Gaines
Related Content